What's the need?
Prostate cancer is the most common male cancer and recently became the most commonly diagnosed cancer in England.
We urgently need to develop new and effective treatments for advanced prostate cancer. It is in the late stages of the disease that prostate cancer kills, yet, surprisingly we are often still using treatments for late stage prostate cancer that are toxic and that prolong life by only a few months.
Globally, the funding of medical research into improved treatments has been minimal; according to the NCRI, just over £22m was spent overall on novel prostate cancer research in the UK in 2018. By way of comparison, £40–£46m has been spent on early stage breast cancer research over the last five years and mortality rates have fallen by 18% since 2014.
This is where PCR comes in. We are here to invest in the science, research and medical breakthroughs of the future.